Cell-based vaccination strategies to induce functional tumorspecific T cells in cancer patients have focused on using autologous dendritic cells. An alternative approach is to use RNA-loaded CD40 activated B cells (CD40-B) that are highly efficient antigen-presenting cells capable of priming naive T cells, boosting memory T-cell responses and breaking tolerance to tumor antigens. The use of tumor RNA as the antigenic payload allows for gene transfer without viruses or vectors and permits major histocompatibility complex (MHC)-independent, multiple-antigen targeting. Here, we use CD40L transfected K562 cells to generate functional CD40-B cells from the peripheral blood of humans and dogs. Testing of RNA-loaded CD40-B cells in dogs allows not only for its development in veterinary medicine but also for determination of its safety and efficacy in a large animal model of spontaneous cancer prior to initiation of human clinical trials. We found that CD40-B cells from healthy humans, healthy dogs and tumor-bearing dogs express increased levels of immune molecules such as MHC and CCR7. Moreover, RNAloaded CD40-B cells induce functional, antigen-specific T cells from healthy dogs and dogs with lymphoma. These findings pave the way for immunotherapy trials using tumor RNA-loaded CD40-B cells to stimulate antitumor immunity in a large animal model of spontaneous neoplasia. Gene Therapy (2008) 15, 955-965;
Introduction
The search for optimal vaccination methods to break tolerance to tumor antigens with the goal of eliciting clinically significant antitumor immune responses in cancer patients has been pursued over decades. Vaccination strategies using autologous dendritic cells (DC) to prime tumor-specific T cells and overcome aspects of immune incompetence in cancer patients have received the greatest attention. [1] [2] [3] The hypothesis is that prior to their injection in patients, ex vivo generated DC can be loaded with tumor-associated antigens which are then degraded by the proteasome into short peptides if necessary, transported into the endoplasmic reticulum, packaged in the groove of newly synthesized major histocompatibility complex (MHC) molecules and delivered as peptide-MHC (pMHC) complexes to the cell membrane. Engagement of the appropriate T-cell receptor (TCR) by these pMHC complexes conveys signals that, in the context of additional costimulatory interactions, activate the T cells. These activated tumor-specific T cells proliferate, produce cytokines and ultimately seek out and lyse tumor cells presenting the antigen.
Numerous clinical trials have evaluated the prospect of DC vaccines as a novel immunotherapy for patients with cancer. [4] [5] [6] [7] [8] Manufacturing issues however are not insignificant. 1 DC do not expand in culture, for example, and large volume leukapheresis is required to secure appropriate numbers of DC precursors to generate such vaccines. [9] [10] [11] As a consequence, application of DC-based vaccines in patients who cannot readily undergo leukapheresis (for example, women with breast cancer who have undergone mastectomy and axillary lymph node dissection or pediatric patients in whom large volume leukapheresis is not feasible) has been challenging.
An alternative approach to DC based vaccines is the use of CD40-activated B cells (CD40-B) as antigen presenting cells (APC). 12, 13 Activation via CD40 enhances the antigen-presenting function of resting B cells, in large part by inducing high-level surface expression of MHC and co-stimulatory molecules. 12, 13 When used with IL-4, CD40 activation causes marked B-cell proliferation in vitro, suggesting that unlike DC, a large number of CD40-B cells can be produced from a small number of precursors. 14, 15 We have previously observed that 100-200 million CD40-B cells can be generated ex vivo from pediatric cancer patients in 3 weeks using only 4-8 ml of blood. 13 Furthermore, peptide-pulsed CD40-B cells are comparable to DC in their ability to stimulate antigen-specific cytotoxic T lymphocyte (CTL) responses 13 and when used in vivo have been shown to stimulate antitumor CD8 + CTLs and delay tumor growth in a murine tumor model. 16 In previous work, we demonstrated that human CD40-B cells can be transfected with tumor antigen mRNA or whole tumor RNA to generate functional antitumor CTL in vitro. 13, 17 The use of RNA as the antigenic payload in CD40-B cells allows gene transfer without the use of vectors or viruses and has the additional benefit of whole-antigen, MHCindependent targeting of tumor antigens. Taken together, these findings indicate that RNA-loaded CD40-B cells may represent a viable alternative to DC based vaccines in stimulating antitumor immunity.
Before evaluating RNA-loaded CD40-B cells in human patients, we have focused on in vivo studies to demonstrate the safety, immunogenicity and potential clinical efficacy of this approach. To do this, we have explored the prospect of treating privately owned animals that present with spontaneous tumors, such as dogs with lymphoma. The domestic dog shares a close phylogenetic relationship with humans and has been widely used to evaluate the safety and efficacy of gene transfer in the treatment of spontaneous genetic disorders. [18] [19] [20] [21] [22] Initial advancements in experimental bone marrow transplantation in research dogs paved the way for the translation of adoptive cellular therapies to human diseases. [23] [24] [25] These studies also demonstrated the utility of canine models for studying the immunobiology of hematopoietic cell transplantation. Privately owned, outbred domestic dogs that develop spontaneous cancers with similar biologic and behavioral characteristics to those in humans are a readily available and clinically relevant resource in which to study new therapeutic approaches to cancer, such as APC vaccination. Indeed, the evaluation of novel immunotherapies in canine cancer patients promises to provide more accurate preclinical data for human trials than rodent models, particularly as dogs are subject to the same environmental influences on tumor initiation and progression as their human counterparts and present with spontaneously occurring malignancies that have already evaded immune recognition. [26] [27] [28] Thus we hypothesize that canine cancer patients can provide a robust test of the in vivo clinical efficacy of therapies aimed at driving antitumor immune responses.
In this study, we demonstrate that large numbers of human and canine CD40-B cells expressing high levels of MHC class II can be generated ex vivo from small amounts of peripheral blood using a novel system of CD40-ligand (CD40L, also known as CD154) transfectants. Furthermore, CD40-B cells from healthy human and canine donors can be loaded with antigen-specific mRNA and used to stimulate functional, antigen-specific T-cell responses. Importantly, here we show that CD40-B cells can be generated from the peripheral blood of canine patients with spontaneously occurring lymphoma and these cells transfected with canine distemper virus hemagglutinin (CDV-HA) mRNA can stimulate canine distemper virus (CDV)-specific T-cell responses in vitro.
Results
Novel culture system for the generation of functional human CD40-B cells
Previously described methods to generate populations of human CD40-B cells rely on murine fibroblasts (NIH3T3) transfected with human CD40L. 12 This culture system is cumbersome, given that feeder cells are adherent and to date cannot be used under good manufacturing practice (GMP) conditions due to its xenogeneic nature. We subsequently modified this culture system with the use of clinical-grade recombinant human trimeric CD40L, but this reagent is no longer available from its manufacturer. To overcome these limitations, the human erythroleukemia cell line K562 was transfected with a hygromycin resistance expression plasmid containing human CD40L to produce an easily maintainable supply of CD40L expressing feeder cells (KtCD40L) in suspension. The parental K562 cells have the additional advantage of having previously been evaluated in human clinical trials of cell-based therapies. Co-culture of KtCD40L with healthy human donor peripheral blood mononuclear cells (PBMC) in addition to IL-4 and cyclosporine led to the generation of a highly enriched population of CD40-B cells that demonstrated robust expansion over five rounds of stimulation within a 30-day period (Figure 1a) . Expansion results using suspension feeder cells (KtCD40L) were similar to those with adherent feeder cells (CD40L transfected murine NIH3T3 cells; Figure 1a ). By day 12-14 in culture, the majority of cells generated with KtCD40L feeder cells expressed markers consistent with the B-cell lineage (CD19, CD79a and CD23) and expressed high surface levels of CD86 and MHC class II (Figure 1b and data not shown).
To determine whether mRNA-loaded human CD40-B cells generated with these culture conditions can induce functional T-cell responses in vitro, we first evaluated PBMC from HLA-A2 + healthy donors co-cultured with autologous CD40-B cells electroporated with either GFP mRNA or mRNA from a FluMP mini-gene. This gene encodes an immunodominant influenza-derived epitope restricted to HLA-A2. 29 Following 7 days of stimulation of PBMC with FluMP mRNA-loaded CD40-B cells, but not GFP mRNA-loaded CD40-B cells, peptide/MHC tetramer analysis revealed marked expansion of FluMP-specific CD8 + T cells (Figure 1c) . Furthermore, FluMP-specific CD8 + T cells stimulated with FluMP mRNA-loaded CD40-B cells efficiently and specifically lysed FluMP peptide-loaded T2 cells or SW40 tumor cells electroporated with FluMP mRNA (Figure 1d ). Control T-cell cultures generated with GFP mRNAloaded CD40-B cells exhibited minimal cytolytic activity against FluMP-loaded targets (Figure 1d) . Furthermore, to demonstrate that the antigen-specific cytolytic T-cell responses elicited by FluMP mRNA-loaded CD40-B cells are MHC class I restricted, cytotoxicity assays were performed using FluMP peptide-loaded T2 target cells pre-incubated with the MHC class I specific monoclonal antibody W6/32 or control mouse immunoglobulin. The addition of W6/32 blocked FluMP-specific cytolytic 
Canine CD40-B cells can be generated from healthy dogs and dogs with lymphoma
To determine whether CD40-B cells can be generated from canine donors using the same culture system, peripheral blood samples were obtained from privately owned healthy dogs and dogs with spontaneous lymphoma. PBMC were cultured with irradiated KtCD40L and recombinant canine IL-4 (rcIL-4) as described in Materials and methods. The substitution of human IL-4 with canine IL-4 was found to be required for optimal generation of canine CD40-B (cCD40-B) cells. + T cells were present in the cultures. These results are similar to those obtained with human CD40-B cells generated using the same KtCD40L culture system. To determine whether cCD40-B cells can be efficiently transfected, cCD40-B cells were electroporated with GFP mRNA and analyzed for GFP and DLA-DR expression by flow cytometry. Transfection efficiencies of 480% were achieved in cCD40-B cells generated from both healthy canine donors and dogs with lymphoma ( Figure  2d and data not shown). CD40-B cell viability after electroporation was similar in human and canine electroporated CD40-B cells (470% at 24 h, data not shown).
cCD40-B cells loaded with CDV-HA mRNA elicit CDV-specific T-cell responses in healthy dogs
Routine vaccination of dogs against CDV generates CTL responses against the hemagglutinin (HA) antigen. [30] [31] [32] To determine whether mRNA-loaded canine CD40-B cells can induce functional T-cell responses in vitro against a viral antigen, cCD40-B cells were generated from three privately owned healthy dogs that had previously received the attenuated live CDV vaccine (Fort Dodge Animal Health, Kansas, IA, USA). cCD40-B cells harvested on day 14 of culture were electroporated with CDV-HA mRNA and co-cultured with autologous PBMC in the presence of rhIL-2 and rhIL-7. After 1 week of in vitro stimulation, T cells were analyzed by cIFN-g ELISpot using CDV-HA mRNA-loaded autologous PHA blasts as target cells (Figure 3a) . More IFN-g secreting T cells were generated from PBMC stimulated with CDV-HA mRNA-loaded CD40-B cells when compared to those stimulated with control GFP mRNA-loaded CD40-B cells. Control T-cell cultures generated with GFP mRNA-loaded cCD40-B cells (negative control) did not secrete IFN-g in response to any target cells.
cCD40-B cells loaded with CDV-HA mRNA elicit CDV-specific IFN-g responses in dogs with spontaneous lymphoma
To determine whether functional T-cell responses can be generated in vitro in canine patients with spontaneously occurring lymphoma using autologous mRNA-loaded cCD40-B cells, cCD40-B cells were generated from a total of four dogs with spontaneous lymphoma, two dogs at the time of diagnosis and two dogs that had completed induction chemotherapy. The dogs studied at diagnosis were a cocker spaniel and a mixed breed with B-cell lymphoma. Dogs that had received chemotherapy were a Weimeraner and a mixed breed. The chemotherapy consisted of a CHOP-based protocol administered over 20 weeks on a cyclical weekly schedule and consisted intravenously) and a tapering dose of daily prednisone (starting at 2 mg kg À1 tapering over the first month). PBMC from these dogs were co-cultured with autologous cCD40-B cells loaded with either CDV-HA mRNA or GFP mRNA. T cells stimulated with CDV-HA mRNA loaded CD40-B cells were capable of secreting IFN-g in response to target cells loaded with CDV-HA mRNA. The number of CDV-specific CTL secreting IFN-g in response to GFP-loaded targets was less (Figure 3b) . In two patients that had finished the chemotherapy protocol and where peripheral blood counts had returned to normal, the number of CDV-specific CTL secreting IFN-g in response to CDV-HA-loaded targets was higher than in response to GFP-loaded targets (Figure 3c ). 
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they interact with cognate naive and memory T cells. The chemokine receptors CCR7 and CXCR4 are upregulated on the surface of mature dendritic cells and mediate their chemotaxis to the lymph nodes. 33, 34 Recent studies have demonstrated that these molecules are also upregulated on the surface of human CD40-B cells. 35 To determine whether canine B cells upregulate CCR7 following CD40 mediated activation, we first cloned and sequenced the canine CCR7 molecule and tested the ability of an antihuman CCR7 monoclonal antibody to cross-react with the canine molecule using flow cytometry. PCR amplification of cDNA obtained from canine CD40-B cells using canine CCR7-specific primers generated a product of 1137 bp. Sequence analysis revealed 100% homology to the predicted canine CCR7 sequence in GenBank (XM_548131). Translation of this product revealed an open reading frame of 1137 base pairs and a protein sequence that is 91% homologous to the human CCR7 sequence (Figure 5a ). The product was cloned and transfected into the K562 cell line. Twenty-four hours later flow cytometric evaluation of these cells using a mouse anti-human CCR7 monoclonal antibody demonstrated the presence of a cross-reactive binding surface protein which was not detected in the control K562 cells transfected with the empty plasmid (Figure 5b ). To determine whether canine B cells upregulate surface expression of canine CCR7 following activation with CD40L, canine CD79a + B cells were evaluated by flow cytometry before and after co-culture with KtCD40L and cIL-4. Following activation, canine CD40-B cells demonstrated a small but distinct shift in upregulation of surface CCR7 expression compared to isotype control mAb (Figure 5c) , with maximal expression 24 h after CD40 ligand stimulation. These results are similar to those previously reported demonstrating the upregulation of CCR7 on human CD40-B cells. 35 
Discussion
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present with spontaneous malignancies that as in humans, have already evaded immune recognition or have actively suppressed antitumor immune responses. Thus, development of the CD40-B cell antigen presentation system as a cell-based vaccine for the treatment of the canine cancer patient was undertaken not only as a potential therapeutic in veterinary medicine but also to serve as a robust test of the safety and clinical efficacy of whole tumor RNA-loaded CD40-B cells in stimulating antitumor immune responses in vivo to an extent that is unparalleled in current rodent models. 28 Previous work has shown that CD40-B cells generated using NIH-3T3 cells transfected with CD40L as feeder cells, and loaded with either antigen-specific RNA or whole tumor RNA, can induce functional T-cell responses in vitro against viral and tumor-associated antigens in pediatric and adult human oncology patients. 13 However, methods consistent with good manufacturing practice limit the use of xenogenic culture systems, and therefore, alternative systems to generate CD40-B cells are required. Attempts using researchgrade human CD40L, CpG or toll receptor agonists combined with IL-4 have demonstrated initial proliferation of culture B cells, but have not been successful in generating the long-term culture stability and expansion that is seen with feeder cell expression of CD40L. 37 Here, we show that the human erythroleukemic cell line K562 can be stably transfected with human CD40L and used in a simple co-culture system to generate activated CD40-B cells that are comparable in their growth characteristics and phenotype to CD40-B cells generated using transfected NIH-3T3 cells. 12 The KtCD40L system has three advantages over NIH-3T3 transfectants; namely, the parental cells are of human origin, grow in suspension culture so are less cumbersome to harvest and require fewer restimulations to support long-term B-cell culture growth. Comparison of the amino-acid sequences of human CD40L (Swissprot no. P29965) and canine CD40L (Swissprot no. 097626) reveals that these sequences share a 79% amino-acid identity. The results reported here demonstrate that K562 cells transfected with human CD40L can stimulate canine B-cell activation and proliferation which is comparable to that achieved in human B-cell cultures and that the phenotype of cCD40-B cells are very similar to human CD40-B cells generated using the same system. Furthermore, we have shown that canine CCR7 is upregulated on the surface of canine CD40-B cells which is comparable with upreglation of CCR7 on human CD40-B cells. 35 This latter finding suggests that following the injection of these APCs in vivo, they should traffic to draining lymph nodes where they can interact with and efficiently activate antigen-specific T-cell responses. Taken together, these findings now allow for this technology to be translated into a spontaneous, large animal cancer model in order to test the safety and efficacy of RNA-loaded CD40-B cells to generate antitumor immunity in vivo.
The ability of human CD40-B cells to stimulate antigen-specific immune responses in vitro is generally accepted; however, the ability of CD40-B cells to stimulate antitumor immunity in vivo and to mediate clinical benefit in patients with spontaneously occurring cancer has not been evaluated. Based on this data, we have initiated a phase I clinical trial in which tumor RNA-loaded CD40-B cells are administered to privately owned, canine patients with spontaneously occurring lymphoma. The primary clinical endpoint is to evaluate safety and toxicity, and secondary endpoints include measuring the stimulation of antitumor immunity and impact on time to disease progression. Current therapy for canine lymphoma relies on combination chemotherapy, following which approximately 90% of dogs achieve complete remission. However, most (480%) canine patients relapse within 1 year and overall survival is less than 10% in most subtypes. 38 In our ongoing clinical trial, each dog enrolled receives autologous tumor RNA-loaded CD40-B cells and CDV-mRNAloaded CD40-B cells (positive control) in the right and left flanks, respectively, once every 3 weeks for a total of three immunizations. To date, 21 canine patients with spontaneous lymphoma have been enrolled, and side effects have been minimal including mild constitutional signs and local injection site reactions.
The studies presented here provide proof of concept that RNA-loaded CD40-B cells can stimulate antigenspecific T-cell responses in canine patients with spontaneous lymphoma and thus pave the way to clinical trials evaluating the safety and potential clinical efficacy of RNA-loaded CD40-B cells in a clinically relevant, spontaneous, large animal cancer model. This trial will provide valuable clinical data necessary for the translation of this novel vaccination strategy to humans with cancer.
Materials and methods

Blood samples and cell lines
Peripheral blood was obtained from healthy adult human donors by leukapheresis after informed consent and with approval of the University of Pennsylvania Institutional Review Board. Blood samples were obtained by phlebotomy from healthy adult dogs or dogs diagnosed with lymphoma, after owner's informed consent and with approval of the University of Pennsylvania's Institutional Animal Care and Use Committee. All dogs had previously received routine CDV vaccination. PBMC from human or canine donors were isolated by Ficoll density gradient centrifugation. The human carcinoma cell lines SW-480 and SKOV3, the human erythroleukemia cell line K562 and the HLA-A2 + transporter associated with antigen processing (TAP)-deficient human T2 cell line 39 were from the American Tissue Culture Collection (Manassas, VA, USA).
Generation of CD40-B cells using human CD40L K562 transfectants
K562 cells were transfected with the pcDNA3.1 + expression plasmid containing human CD40L and a hygromycin resistance cassette. Transfected cells (KtCD40L) with 42 log mean fluorescence intensity of CD40L expression were sorted by flow cytometry and maintained under hygromycin selection, using culture conditions modified from previously published human culture conditions. 12, 13 To generate CD40-B cells from human and canine PBMC, KtCD40L were lethally irradiated (96 Gy) and plated in six-well plates at 1 Â 10 6 cells per well. Five million PBMC were resuspended in 4 ml of B-cell culture medium consisting of Iscove's modified Dulbecco medium (IMDM) supplemented with 10% 
Antibodies and flow cytometry
Human PBMC and CD40-B cells were analyzed for cell surface molecule immunophenotype as previously described. 13 Canine PBMC and CD40-B cells were analyzed by flow cytometry using the following antibodies: rat anti-canine CD3 (Serotec, Oxford, UK), rat anti-canine B cell (Serotec), rat anti-DLA-DR (Serotec), mouse antihuman CD79a (BD PharMingen, San Diego, CA, USA) and mouse anti-human CCR7 (R&D Systems). For intracellular staining, cells were fixed and permeabilized (Fix and Perm solution, Caltag Laboratories, San Francisco, CA, USA) prior to staining. In experiments to analyze KtCD40L-induced B-cell proliferation, canine PBMC were washed twice with PBS, resuspended to a concentration of 10 Â 10 6 ml À1 and labeled with CFSE (Molecular Probes, Eugene, OR, USA) 1.25 mM for 5 min at room temperature. Labeling was quenched with 5% FCS and cells were washed three times in B-cell media prior to stimulation with KtCD40L, as described above.
mRNA preparation mRNA encoding full-length CDV-HA or eGFP genes was prepared from template plasmids containing the fulllength cDNA (pCIneo-CDV-HA or pVA67D-eGFP) by in vitro transcription using the T7 RNA polymerase promoter and the mMessage mMachine kit (Ambion, Austin, TX, USA). Transcribed RNA was polyadenylated at the 3 0 terminus using the Escherichia coli Poly(A) Polymerase I (E-PAP), treated with DNase to remove plasmid sequences and purified by acidic phenol/ chloroform extraction and RNeasy column separation (Qiagen, Valencia, CA, USA). Measurement of OD 260 and formaldehyde denaturing gel electrophoresis were used to determine quantity and quality of mRNA.
Establishment of T-cell cultures using RNA-electroporated CD40-B cells
For RNA electroporation of CD40-B cells, CD40-B cells were harvested after 2 weeks of culture, washed twice in PBS, resuspended at 2-2.5 Â 10 6 per 100 ml of Nucleofector B solution (Amaxa, Cologne, Germany) and electroporated with 2 mg mRNA/sample (pulse program U08). Expression of electroporated mRNA in CD40-B cells was determined by GFP expression 24 h after electroporation. Electroporated human or canine CD40-B cells were then washed in T-cell medium (RPMI with 10% human AB serum, 2 mM glutamine, 20 mM HEPES and 15 mg ml À1 gentamycin) and plated at 5 Â 10 5 cells per well with 3 Â 10 6 PBMC/well in 24-well plates. Cultures were supplemented with 500 U ml À1 rhIL-4 or rcIL-4 and 10 ng ml À1 rhIL-7 (Sigma, St Louis, MO, USA) on day 0 and 20 U ml À1 rhIL-2 (Chiron, Emeryville, CA, USA) on days 1 and 4.
Chromium 51 release assay
Chromium release assays were performed as previously described. 40 Target cells included T2 cells loaded with 10 mg ml À1 peptide (New England Peptide, Fitchburg, MA, USA) and 2.5 mg ml À1 b2-microglobulin (Sigma) and SW480 cells loaded with 10 mg ml À1 peptide for evaluation of human CTL activity. The HLA-A2-binding HTLV-1 L11 tax peptide served as a negative control peptide. Standard deviation was less than 5%. For MHC class I blocking studies, the MHC-specific monoclonal antibody W6/32 (Serotec) and control mouse IgG antibody (Jackson Immuno Research, West Grove, PA, USA) were used at a final concentration of 10 mg ml
À1
. Antibodies were incubated with target cells for 30 min at 37 1C before the addition of T cells.
Tetramer analysis
Peptide/MHC tetramer for the HLA-A2-restricted dominant epitope of FluMP (GILGFVFTL) and negative control HLA-A2 tetramer were purchased from Immunomics (San Diego, CA, USA). Peptide/MHC tetramer analysis was performed as previously described. 13 
ELISPOT analysis
For IFN-g analysis, T-cell cultures at 2.5 Â 10 4 cells per well were added to ImmunoSpot plates (Cellular Technology, Cleveland, OH, USA) precoated with 10 mg ml À1 anti-IFN-g mAb (Mabtech, Nacka, Sweden) in the presence of stimulator cells overnight at 37 1C. Stimulator cells included T2 cells at 5 Â 10 5 cells per well with 5 mg ml À1 peptide and 1 mg ml À1 b2-microglobulin. After 24 h at 37 1C, wells were developed as previously described 41 and were counted using a Prior ProScan analyzer and Image Pro Plus software (Hitech Instruments, Edgemont, PA, USA). For IFN-g analysis of CD40-B cell-stimulated canine T cells, autologous PBMC were stimulated with phytohemagglutinin (PHA (5 mg ml À1 ); Sigma) and rhIL-2 for 5 days, electroporated with CDV mRNA or GFP mRNA and used as targets in co-cultures with RNA-loaded CD40-B cell-stimulated T cells (2.5 Â 10 4 cells per well). ELISPOT analysis was performed using the canine IFN-g ELISPOT kit to detect antigen-specific responder cells (R&D Systems).
Quantitative real-time PCR evaluation
Total RNA was extracted from T cells stimulated with CDV-HA-loaded CD40-B cells 36 h after restimulation, using the Qiagen RNeasy Isolation System (Qiagen). Reverse transcription was performed using random hexamers and Superscript II reverse transcriptase (Invitrogen Corp., Carlsbad. CA, USA) according to the manufacturer's instructions. Taqman PCR primers and probes for canine IFN-g, IL-4, IL-10, TGF-b and the eukaryotic 18S ribosomal protein were obtained from Applied Biosystems (Foster City, CA, USA). Transcript sequences for canine perforin (XM_546148) were obtained from the National Centre for Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov) and
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were analyzed for secondary DNA structure using M-fold 42 (http://frontend.bioinfo.rpi.edu/applications/ mfold/cgi-bin/dna-form1.cgi. Primers for canine perforin were designed using Primer 3 software (http:// frodo.wi.mit.edu) with the maximum self-complementarity score set at 5 and the maximum 3 self-complementarity score set to 0 to minimize primer-dimer formation. Primers were synthesized by Invitrogen Corp. The following primer sequences were used in qRT-PCR analysis: canine perforin forward, 5
0 -CCAAGACTAT GGCTGGGATG-3 0 ; canine perforin reverse, 5 0 -GCAC TTGGCAATGTAGGAGAA-3 0 . Annealing temperatures of all primers were 60 1C. qRT-PCR primers used for canine b-actin have been previously described. 43 Realtime PCR assays for canine perforin and b-actin were performed using SYBR Green I based detection (Applied Biosystems). SYBR Green and Taqman assays were run in triplicate at standard conditions using a sequence detector (ABI 7500; Applied Biosystems) and data were analyzed on Taqman Assays on Demand (Applied Biosystems). Taqman assays utilized the 18S ribosomal subunit as an endogenous control and SYBR Green assays utilized b-actin as an endogenous control. Dissociation curves were performed after each experiment that used SYBR green technology to confirm the specificity of product amplification and ensure that false positive results were not obtained.
Cloning and characterization of canine CCR7
Total RNA was extracted from canine CD40-B cells using RNA Stat 60 (IsoTex Diagnostics, Inc. Friendswood, TX, USA) according to the manufacturers' instructions. Reverse transcription was performed using random hexamers and the first strand cDNA synthesis system (Amersham Pharmacia Biotech, Little Chalfont, England). Forward and reverse primers for canine CCR7 were designed based on the predicted sequence for CCR7 (PubMed XM_548131) with BAMHI and XHOI restriction sites incorporated into the forward and reverse primers respectively (cCCR7 forward primer: 5 0 -GGATC CATGGACCTGGGGAAACCAATGAAAAG-3 0 ; cCCR7 reverse primer: 5 0 -CTCGAGCTACGGGGAGAAGGTGG TGGTGGTC-3 0 ). Cycling conditions were as follows: denaturation, 94 1C for 3 min; annealing, 64 1C for 30 s; extension, 72 1C for 3 min. PCR products were cloned into the pcDNA3.1 + expression vector and sequenced. K562 cells were transfected with the empty pcDNA3.1 + plasmid or pcDNA3.1 + containing canine CCR7 using the Amaxa transfection system (Amaxa). Twenty-four hours later, cells were analyzed for the surface expression of canine CCR7 using a monoclonal mouse antihuman CCR7 (clone 150503; R&D Systems).
